Fibrosing colonopathy is a rare condition in which the wall of the colon becomes thickened with scar tissue, creating narrowed segments that can partially or completely block the bowel. First identified in 1994, it occurs almost exclusively in people with cystic fibrosis who take high doses of pancreatic enzyme supplements to help digest food. The condition primarily affects the ascending colon (the first portion of the large intestine) and is most common in children under 12.
What Happens Inside the Colon
In fibrosing colonopathy, the colon develops long, spindle-shaped areas of narrowing called strictures. Under a microscope, the affected tissue shows a distinctive pattern: dense scar tissue builds up in the layer just beneath the inner lining of the colon, while the muscular wall thickens significantly. The inner surface takes on a cobblestone-like appearance, and the tissue is infiltrated by a type of immune cell associated with allergic and inflammatory reactions.
These changes make the colon progressively stiffer and narrower. Imaging studies of affected patients typically reveal strictures, loss of the colon’s normal pouch-like folds, and visible shortening of the organ. Over time, the narrowing can become severe enough to obstruct the passage of stool entirely.
The Link to Pancreatic Enzyme Supplements
People with cystic fibrosis often have a pancreas that cannot produce enough digestive enzymes, so they take enzyme supplements (particularly lipase, which breaks down fat) with every meal. Fibrosing colonopathy is strongly tied to the dose of these supplements. A landmark study published in the New England Journal of Medicine found that children taking between 24,001 and 50,000 units of lipase per kilogram of body weight per day had roughly 11 times the risk of developing the condition compared to those on lower doses. Children taking more than 50,000 units per kilogram per day faced a risk nearly 200 times higher.
The dose alone doesn’t fully explain the problem, though. Researchers identified a specific coating used on high-strength enzyme capsules, a polymer called methacrylic acid copolymer, as a major contributor. This coating is designed to protect the enzymes from stomach acid so they release in the intestine. In animal studies, direct exposure to this polymer produced colon damage strikingly similar to fibrosing colonopathy, including dense scar tissue formation beneath the lining, at dose levels comparable to what humans would ingest. The individual chemical components of the polymer did not cause the same damage when tested separately, pointing to the intact coating material as the culprit.
Who Is Most at Risk
The Cystic Fibrosis Foundation identifies several groups at highest risk:
- Children younger than 12, who appear more vulnerable than older patients
- Patients taking more than 6,000 lipase units per kilogram per meal for longer than six months
- Those with a history of meconium ileus (a bowel obstruction at birth common in cystic fibrosis) or distal intestinal obstruction syndrome
- Patients who have had previous intestinal surgery
While the vast majority of cases occur in cystic fibrosis, rare reports have documented fibrosing colonopathy in patients with other conditions who take enteric-coated medications, including a medication used for cystinosis (a different metabolic disease). This suggests the condition may not be exclusive to cystic fibrosis itself but rather to the medications and coatings involved.
Symptoms to Recognize
The symptoms of fibrosing colonopathy reflect a colon that is progressively narrowing. Children and adults with the condition typically experience abdominal pain, bloating, and changes in bowel habits. As strictures worsen, signs of partial or complete bowel obstruction can develop, including severe abdominal distension, vomiting, and an inability to pass stool. Poor weight gain or weight loss is common in affected children, partly because the underlying cystic fibrosis already makes nutrient absorption difficult and partly because the damaged colon further impairs digestion.
Because many of these symptoms overlap with common cystic fibrosis complications like distal intestinal obstruction syndrome, fibrosing colonopathy can be difficult to distinguish without imaging or direct visualization of the colon.
How It Is Diagnosed
A contrast enema (where dye is introduced into the colon and X-rays are taken) is one of the key diagnostic tools. The characteristic findings include strictures, loss of the normal haustral folds that give the colon its segmented appearance, and shortening of the colon’s overall length. CT scans and ultrasound can also reveal wall thickening and narrowing.
A definitive diagnosis, however, comes from examining tissue. When a biopsy or surgical specimen shows the combination of dense submucosal fibrosis, thickened muscular wall, and inflammatory cell infiltration, the diagnosis is confirmed.
Treatment and Outcomes
The first step in management is reducing the enzyme dose. In some milder cases, lowering the lipase intake and monitoring symptoms is enough. In one reported case involving a different medication with a similar enteric coating, switching from the coated formulation to an uncoated version led to resolution of the strictures without surgery.
For patients with significant narrowing that causes obstruction or severe symptoms, surgery becomes necessary. In one surgical series, nine patients required removal of part or all of the colon: five had the right side of the colon removed, three had more extensive resections leaving only the lower portion of the colon, and one needed near-total removal of the colon with creation of an ostomy bag. Outcomes after surgery are generally good when the affected segment is fully removed.
Three of four patients in that same series who were managed without surgery had milder symptoms and were followed conservatively, suggesting that not every case progresses to the point of requiring an operation. Long-term data remains limited, however. Most case reports do not track patients far enough to know how often symptoms recur after treatment or whether the colon fully heals in those managed without surgery.
Current Dosing Guidelines
After fibrosing colonopathy was linked to high-dose enzyme therapy in the mid-1990s, the Cystic Fibrosis Foundation and the FDA jointly published dosing guidelines that remain in effect. The current recommendations set a caution threshold at 2,500 lipase units per kilogram per meal, or 4,000 lipase units per gram of dietary fat. Doses above 6,000 lipase units per kilogram per meal have been directly associated with fibrosing colonopathy and should not be used.
Patients already on doses above these limits are advised to gradually taper down rather than abruptly reducing their enzymes. Since the implementation of these guidelines, fibrosing colonopathy has become considerably less common, though it has not disappeared entirely. The condition serves as an important reminder that even essential, life-improving medications carry dose-dependent risks that require careful monitoring.